HEMOSOL - 500 Beiträge pro Seite
eröffnet am 10.08.04 10:03:15 von
neuester Beitrag 22.10.04 14:17:56 von
neuester Beitrag 22.10.04 14:17:56 von
Beiträge: 2
ID: 890.781
ID: 890.781
Aufrufe heute: 0
Gesamt: 761
Gesamt: 761
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 8088 | |
| vor 38 Minuten | 6364 | |
| heute 18:07 | 3131 | |
| vor 1 Stunde | 3103 | |
| vor 1 Stunde | 2362 | |
| gestern 18:44 | 2355 | |
| vor 37 Minuten | 1922 | |
| heute 17:49 | 1881 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.017,55 | +0,44 | 240 | |||
| 2. | 2. | 168,86 | +0,48 | 95 | |||
| 3. | 3. | 9,7000 | +12,27 | 73 | |||
| 4. | 14. | 6,1800 | -0,71 | 70 | |||
| 5. | 11. | 0,1880 | +0,80 | 57 | |||
| 6. | 7. | 0,9850 | -1,50 | 50 | |||
| 7. | 12. | 0,1590 | +4,88 | 48 | |||
| 8. | 24. | 60,80 | -2,63 | 39 |
Feedback
gestern diese zahlen und in kanada nur 13%!
was soll das...
Business - Canadian Press
Hemosol Corp. posts Q2 profit of $2.9M after $16M deal with MDS
Mon Aug 9, 8:15 AM ET
TORONTO (CP) - Blood products company Hemosol Corp., recently restructured and benefiting from MDS Inc`s $16-million cash infusion, is reporting a $2.9-million profit in the second quarter.
Related Quotes
HML
I
DJIA
NASDAQ
^SPC
N/A
N/A
9820.72
1774.64
N/A
N/A
N/A
+5.39
-2.25
N/A
delayed 20 mins - disclaimer
Quote Data provided by Reuters
Top-Grade Tech
The best gadgets to help students through the year, from new phones to gizmos for locking down your stuff.
For the quarter ended June 30, net income amounted to five cents a share, contrasting with a loss of $9.6 million or 21 cents per share a year earlier, the Toronto-based company (TSX:HML - news) said Monday.
The financial results of Hemosol Corp. are compared with those of predecessor Hemosol Inc., which was renamed LPBP Inc. after completion a reorganization involving Hemosol Inc., its shareholders and MDS.
"During the quarter, Hemosol focused on negotiating and completing agreements to formalize key relationships that will drive the company`s growth strategy in the near future," CEO Lee Hartwell said in a release.
"Completion of the reorganization has provided us with the financial flexibility to proceed with a series of value-creation initiatives that we believe will allow us to leverage the Meadowpine manufacturing facility and further develop our pipeline of oxygen therapeutics and drug delivery technologies."
The MDS deal allows the company to pursue development of blood substitute Hemolink and other blood-related product, as well as advance in a strategic alliance with ProMetic Biosciences and the American National Red Cross.
In early June, Hemosol announced it had signed licence and alliance agreements with ProMetic Biosciences, a subsidiary of ProMetic Life Sciences Inc. (TSX:I - news), to license the Cascade technology developed by ProMetic and the American Red Cross (news - web sites) for the separation of therapeutic proteins from human plasma.
was soll das...
Business - Canadian Press
Hemosol Corp. posts Q2 profit of $2.9M after $16M deal with MDS
Mon Aug 9, 8:15 AM ET
TORONTO (CP) - Blood products company Hemosol Corp., recently restructured and benefiting from MDS Inc`s $16-million cash infusion, is reporting a $2.9-million profit in the second quarter.
Related Quotes
HML
I
DJIA
NASDAQ
^SPC
N/A
N/A
9820.72
1774.64
N/A
N/A
N/A
+5.39
-2.25
N/A
delayed 20 mins - disclaimer
Quote Data provided by Reuters
Top-Grade Tech
The best gadgets to help students through the year, from new phones to gizmos for locking down your stuff.
For the quarter ended June 30, net income amounted to five cents a share, contrasting with a loss of $9.6 million or 21 cents per share a year earlier, the Toronto-based company (TSX:HML - news) said Monday.
The financial results of Hemosol Corp. are compared with those of predecessor Hemosol Inc., which was renamed LPBP Inc. after completion a reorganization involving Hemosol Inc., its shareholders and MDS.
"During the quarter, Hemosol focused on negotiating and completing agreements to formalize key relationships that will drive the company`s growth strategy in the near future," CEO Lee Hartwell said in a release.
"Completion of the reorganization has provided us with the financial flexibility to proceed with a series of value-creation initiatives that we believe will allow us to leverage the Meadowpine manufacturing facility and further develop our pipeline of oxygen therapeutics and drug delivery technologies."
The MDS deal allows the company to pursue development of blood substitute Hemolink and other blood-related product, as well as advance in a strategic alliance with ProMetic Biosciences and the American National Red Cross.
In early June, Hemosol announced it had signed licence and alliance agreements with ProMetic Biosciences, a subsidiary of ProMetic Life Sciences Inc. (TSX:I - news), to license the Cascade technology developed by ProMetic and the American Red Cross (news - web sites) for the separation of therapeutic proteins from human plasma.
Hallo,
gibt es irgendetwas neues über HEMOSOL
gibt es irgendetwas neues über HEMOSOL
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 241 | ||
| 100 | ||
| 81 | ||
| 74 | ||
| 51 | ||
| 49 | ||
| 49 | ||
| 37 | ||
| 37 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 32 | ||
| 30 | ||
| 27 | ||
| 25 | ||
| 24 | ||
| 22 | ||
| 20 | ||
| 18 | ||
| 17 | ||
| 16 |
